UNLABELLED: Approximately one third of the adult U.S. population suffers from some type of on-going, chronic pain annually, and many more will have some type of acute pain associated with trauma or surgery. First-line therapies for moderate to severe pain include prescriptions for common mu opioid receptor agonists such as morphine and its various derivatives. The epidemic use, misuse and diversion of prescription opioids have highlighted just one of the adverse effects of mu opioid analgesics. Alternative approaches include novel opioids that target delta or kappa opioid receptors, or compounds that interact with two or more of the opioid receptors. AIMS: Here we report the pharmacology of a newly synthesized bifunctional opioid agonist (RV-Jim-C3) derived from combined structures of fentanyl and enkephalin in rodents. RV-Jim-C3 has high affinity binding to both mu and delta opioid receptors. MAIN METHODS: Mice and rats were used to test RV-Jim-C3 in a tailflick test with and without opioid selective antagonist for antinociception. RV-Jim-C3 was tested for anti-inflammatory and antihypersensitivity effects in a model of formalin-induced flinching and spinal nerve ligation. To rule out motor impairment, rotarod was tested in rats. KEY FINDINGS: RV-Jim-C3 demonstrates potent-efficacious activity in several in vivo pain models including inflammatory pain, antihyperalgesia and antiallodynic with no significant motor impairment. SIGNIFICANCE: This is the first report of a fentanyl-based structure with delta and mu opioid receptor activity that exhibits outstanding antinociceptive efficacy in neuropathic pain, reducing the propensity of unwanted side effects driven by current therapies that are unifunctional mu opioid agonists.
UNLABELLED: Approximately one third of the adult U.S. population suffers from some type of on-going, chronic pain annually, and many more will have some type of acute pain associated with trauma or surgery. First-line therapies for moderate to severe pain include prescriptions for common mu opioid receptor agonists such as morphine and its various derivatives. The epidemic use, misuse and diversion of prescription opioids have highlighted just one of the adverse effects of mu opioid analgesics. Alternative approaches include novel opioids that target delta or kappa opioid receptors, or compounds that interact with two or more of the opioid receptors. AIMS: Here we report the pharmacology of a newly synthesized bifunctional opioid agonist (RV-Jim-C3) derived from combined structures of fentanyl and enkephalin in rodents. RV-Jim-C3 has high affinity binding to both mu and delta opioid receptors. MAIN METHODS:Mice and rats were used to test RV-Jim-C3 in a tailflick test with and without opioid selective antagonist for antinociception. RV-Jim-C3 was tested for anti-inflammatory and antihypersensitivity effects in a model of formalin-induced flinching and spinal nerve ligation. To rule out motor impairment, rotarod was tested in rats. KEY FINDINGS: RV-Jim-C3 demonstrates potent-efficacious activity in several in vivo pain models including inflammatory pain, antihyperalgesia and antiallodynic with no significant motor impairment. SIGNIFICANCE: This is the first report of a fentanyl-based structure with delta and mu opioid receptor activity that exhibits outstanding antinociceptive efficacy in neuropathic pain, reducing the propensity of unwanted side effects driven by current therapies that are unifunctional mu opioid agonists.
Authors: Henry I Mosberg; Larisa Yeomans; Aubrie A Harland; Aaron M Bender; Katarzyna Sobczyk-Kojiro; Jessica P Anand; Mary J Clark; Emily M Jutkiewicz; John R Traynor Journal: J Med Chem Date: 2013-02-27 Impact factor: 7.446
Authors: Jai Shankar K Yadlapalli; Benjamin M Ford; Amit Ketkar; Anqi Wan; Narasimha R Penthala; Robert L Eoff; Paul L Prather; Maxim Dobretsov; Peter A Crooks Journal: Pharmacol Res Date: 2016-09-13 Impact factor: 7.658
Authors: M F Bird; R S Vardanyan; V J Hruby; G Calò; R Guerrini; S Salvadori; C Trapella; J McDonald; D J Rowbotham; D G Lambert Journal: Br J Anaesth Date: 2015-02-13 Impact factor: 9.166
Authors: Jai Shankar K Yadlapalli; Navdeep Dogra; Anqi W Walbaum; William D Wessinger; Paul L Prather; Peter A Crooks; Maxim Dobretsov Journal: Anesth Analg Date: 2017-09 Impact factor: 5.108
Authors: Ruben S Vardanyan; James P Cain; Saghar Mowlazadeh Haghighi; Vlad K Kumirov; Mary I McIntosh; Alexander J Sandweiss; Frank Porreca; Victor J Hruby Journal: J Heterocycl Chem Date: 2016-06-01 Impact factor: 2.193
Authors: Thomas Günther; Pooja Dasgupta; Anika Mann; Elke Miess; Andrea Kliewer; Sebastian Fritzwanker; Ralph Steinborn; Stefan Schulz Journal: Br J Pharmacol Date: 2017-05-26 Impact factor: 8.739
Authors: Srinivas Deekonda; Jacob Cole; Sydney Sunna; David Rankin; Tally M Largent-Milnes; Peg Davis; Neemah M BassiriRad; Josephine Lai; Todd W Vanderah; Frank Porecca; Victor J Hruby Journal: Bioorg Med Chem Lett Date: 2015-11-03 Impact factor: 2.823